In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, participants will receive ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally disorder progression or even the individuals are not able to tolerate the study drugs. For all movement cytometry experiments, 10,000 cells for each replicate ended https://abbv-744brd4inhibitioninc79013.dailyhitblog.com/37402106/5-easy-facts-about-abbv-744-brd4-inhibitor-mechanism-of-action-described